CHOOSE THE **RIGHT TREATMENT** FOR EACH PATIENT

IndiTreat®
by 2cureX

INDITREAT®. DRUG SENSITIVITY TESTING IN ONCOLOGY.

IndiTreat® is a family of IVD tests developed and run by 2cureX as an aid to predict an individual cancer patient's response and resistance to different drug regimens. The tests assess the effect of exposing patient-derived 3D tumoroids in vitro to various drugs and drug combinations.

As a result, IndiTreat® enables treating physicians to design a truly personalized treatment for each patient.

PRECISION ONCOLOGY FOR ALL CANCER PATIENTS

6.8 M new cases per year
Advanced or Metastatic Cancer

1.9 M {28%}
Have a biomarker to guide therapy

4.9 M {72%}
Therapy is decided based on "average benefits (PFS/OS)" but is not individualized

IndiTreat® provides guidance where conventional biomarkers are not available



1.2 M {63%}
Do not benefit from the selected therapy

IndiTreat® complements conventional biomarkers and improves prediction of treatment response

WHY INDITREAT®?

3D TUMOROIDS REPLICATE THE PATIENT'S ORIGINAL TUMOR

At 2cureX we grow tumor replicas, called tumoroids, from cell clusters from the patient's tumors. The three-dimensional structures better replicate the original tumor biology, including heterogeneity, than two-dimensional methods and so provide a more reliable prediction of the patient's response to a specific treatment.

TREATMENT GUIDANCE POWERED BY ARTIFICIAL INTELLIGENCE / MACHINE LEARNING

The effect of the cancer drugs on the tumoroids is assessed by capturing and interpreting small variations in size and shape and comparing those variations with a vast proprietary database of reference images. We have developed our own Convolutional Neural Network that combines data from brightfield and fluorescence images of the tumoroids in a dynamic analysis and converts them into a quantitative measurement of response to treatment.

TAILORED FOR CLINICAL USE

2cureX offers IndiTreat® tests as a lab service. The use of the IndiTreat® technology in a clinical setting has been validated in the TICC trial, the first prospective interventional trial, in which a 3D functional test was used to guide treatment.

The design of the various drug panels supports specific treatment decisions throughout the patient lifecycle, and the cost and turnaround time make the IndiTreat® tests suitable for use in clinical practice. Turnaround time from biopsy to the final report is around three weeks.

INDITREAT® PROCESS





INDITREAT® GUIDANCE AND DRUG PANELS

The IndiTreat® tests measure the sensitivity of a particular patient's tumoroids to a specific panel of cancer treatments and compares it to a reference population of tumoroids treated with the same drugs.

The results are categorized from "Low Sensitivity" to "High Sensitivity" and positioned in a reference graph. The IndiTreat® results are summarized in a table *(figure 1.)* showing the sensitivity profile of the patient tumor to each drug. The available drug panels are shown in *(figure 2.)*.

PATIENT A – SENSITIVITY RESULT

DRUG TESTED	Low Sensitivity	Medium Low Sensitivity	Medium High Sensitivity	High Sensitivity
Drug A		◆		
Drug B		◆		
Drug C	◆			
Drug D				◆
Drug E			◆	

Figure 1.

INDITREAT® METASTATIC COLORECTAL CANCER TESTS

IndiTreat® mCRC Start	IndiTreat® mCRC Extend	IndiTreat® mCRC Explore
5-fluorouracil (5FU)	FOLFOX	Regorafenib
FOLFOX	FOLFIRI	Trifluridine + tipiracil
FOLFIRI	FOLFOXIRI	Gemcitabine + 5FU
FOLFOXIRI	Regorafenib	Mitomycin + 5FU
	Trifluridine + tipiracil	Temozolamide + irinotecan

Figure 2.

ABOUT 2CUREX

2cureX is an in-vitro diagnostics company founded in 2006 with the aim of matching patients to treatments and improving the way in which cancer care is delivered. 2cureX is headquartered in Copenhagen, Denmark, and has a research site in Hamburg, Germany.

MISSION

Our Mission is “Improving patients’ outcomes by establishing individualized drug sensitivity profiling as routine practice in Oncology, so that all treatment decisions are supported by a personal test”.

FOCUSED ON CLINICAL USE

We are leaders in the use of patient-derived 3D tumoroids to assess the effect of drugs on individual patients and are committed to bringing this technology to routine clinical practice. To that end we have developed the IndiTreat® family of assays, with an initial focus on GI cancers.

The company is EN ISO 13485 certified.

ISO 13485
BUREAU VERITAS
Certification Denmark A/S

2CX-BR-IND.02

IndiTreat®
by 2cureX

2cureX
Fruebjergvej 3
2100 Copenhagen
Denmark

Mail: support@2curex.com
www.inditreat.com